Ann: HEP B PreClinical Results, page-60

Bluebird Bio gets crushed today (-37%) due to differing results for patients of their drug  LentiGlobin BB305.

http://www.bizjournals.com/boston/b...data-on-bluebird-bios-potential-for-gene.html

And this is why you don't release viral load data yet if you are Benitec.  Wait until the full cohort is complete and monitored for however long it needs to be.

I always said Bluebird's market cap was an absurd joke.  The joke is still ongoing as they still have a 3 billion market cap.  Won't be surprised if they go back to the 10$ where they belong.